TriangleDISEASE & TREATMENT SETTING
KEYTRUDA QLEX: unresectable metastatic Biliary tract cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.12 Biliary Tract Cancer KEYTRUDA QLEX, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
Broader topic: Malignant Biliary Tract Neoplasm
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- unresectable
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for KEYTRUDA QLEX (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.12 Biliary Tract Cancer KEYTRUDA QLEX, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
Study evidence for this setting
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Milademetan in Advanced/Metastatic Solid Tumors
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice